Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms-Reference-Cited by-同舟云学术

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms

Published:2006-07-13 Issue:10 Volume:93 Page:1270-1276
ISSN:0007-1323
Container-title:British Journal of Surgery
language:en
Short-container-title:

Author:

Yan T D¹,Links M²,Xu Z Y¹,Kam P C³,Glenn D⁴,Morris D L¹

Affiliation:

1. Peritoneal Surface Malignancy Program, Department of Surgery, St George Hospital, Sydney, New South Wales, Australia

2. Peritoneal Surface Malignancy Program, Department of Medical Oncology, St George Hospital, Sydney, New South Wales, Australia

3. Peritoneal Surface Malignancy Program, Department of Anesthesiology, St George Hospital, Sydney, New South Wales, Australia

4. Peritoneal Surface Malignancy Program, Department of Radiology, St George Hospital, Sydney, New South Wales, Australia

Abstract

Abstract Background Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has been used to treat pseudomyxoma peritonei. The aim of this prospective study was to evaluate survival outcome and treatment-related prognostic markers in patients who underwent CRS and PIC for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Methods Survival data and 12 clinicopathological and treatment-related prognostic variables for survival were obtained prospectively in 50 consecutive patients (23 men). Univariate analysis was used to determine their prognostic significance for overall survival, determined from the time of CRS. Results The mean(s.d.) age was 52(12) years. Eighteen patients had moderate complications, and six patients had severe complications that required operation or intensive care support. Two patients died after surgery. The actuarial 5-year survival rate was 69 per cent. Univariate analysis demonstrated that the extent of previous surgery (P = 0·045) and Ronnett's histopathological classification (P < 0·001) were significantly related to overall survival. Conclusion CRS combined with PIC was associated with improved survival in patients with less extensive previous surgery and diffuse peritoneal adenomucinosis histopathological type.

Publisher

Oxford University Press (OUP)

Subject

Surgery

Link

http://academic.oup.com/bjs/article-pdf/93/10/1270/36686311/bjs5427.pdf

Reference26 articles.

1. A new standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?;Sugarbaker;Lancet Oncol,2006

2. The etiology, clinical presentation and management of pseudomyxoma peritonei;Moran;Surg Oncol Clin N Am,2003

3. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread;Carmignani;Cancer Metastasis Rev,2003

4. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach;Gough;Ann Surg,1994

5. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy;Miner;Ann Surg,2005

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei;Pleura and Peritoneum;2023-03-01

2. Optimizing risk factors influence Intensive Care stay after Hyperthermic Intraperitoneal Chemotherapy? An observational cohort study;Cancer Treatment and Research Communications;2022

3. The Landmark Series: Appendiceal Primary Peritoneal Surface Malignancy;Annals of Surgical Oncology;2021-12-01

4. Coagulopathy and Venous Thromboembolic Events Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy;Annals of Surgical Oncology;2021-04-10

5. Anesthesia for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC);Textbook of Onco-Anesthesiology;2021